Riomet Er is a drug owned by Sun Pharmaceutical Industries Ltd. It is protected by 1 US drug patent filed in 2019 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be May 01, 2035. Details of Riomet Er's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9962336 | Extended release suspension compositions |
May, 2035
(10 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Riomet Er's patents.
Latest Legal Activities on Riomet Er's Patents
Given below is the list of recent legal activities going on the following patents of Riomet Er.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 08 Nov, 2021 | US9962336 |
| Email Notification Critical | 21 Jan, 2021 | US9962336 |
| Change in Power of Attorney (May Include Associate POA) Critical | 21 Jan, 2021 | US9962336 |
| Correspondence Address Change Critical | 19 Jan, 2021 | US9962336 |
| Correspondence Address Change Critical | 20 Jul, 2020 | US9962336 |
| Recordation of Patent Grant Mailed Critical | 08 May, 2018 | US9962336 |
| Patent Issue Date Used in PTA Calculation Critical | 08 May, 2018 | US9962336 |
| Email Notification Critical | 19 Apr, 2018 | US9962336 |
| Issue Notification Mailed Critical | 18 Apr, 2018 | US9962336 |
| Application Is Considered Ready for Issue Critical | 30 Mar, 2018 | US9962336 |
Several oppositions have been filed on Riomet Er's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Riomet Er's generic, the next section provides detailed information on ongoing and past EP oppositions related to Riomet Er patents.
Riomet Er's Oppositions Filed in EPO
Riomet Er has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Aug 11, 2021, by Reckitt Benckiser Health Limited. This opposition was filed on patent number EP15786792A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP15786792A | Aug, 2021 | Reckitt Benckiser Health Limited | Granted and Under Opposition |
US patents provide insights into the exclusivity only within the United States, but Riomet Er is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Riomet Er's family patents as well as insights into ongoing legal events on those patents.
Riomet Er's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Riomet Er's generic launch date based on the expiry of its last outstanding patent is estimated to be May 01, 2035 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Riomet Er Generic API suppliers:
Metformin Hydrochloride is the generic name for the brand Riomet Er. 68 different companies have already filed for the generic of Riomet Er, with Apotex having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Riomet Er's generic
Alternative Brands for Riomet Er
There are several other brand drugs using the same active ingredient (Metformin Hydrochloride) as Riomet Er. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |||||
|---|---|---|---|---|---|---|
| Andrx Labs Llc |
| |||||
| Astrazeneca Ab |
| |||||
| Boehringer Ingelheim |
| |||||
| Bristol Myers Squibb |
| |||||
| Emd Serono Inc |
| |||||
| Janssen Pharms |
| |||||
| Msd Sub Merck |
| |||||
| Novo Nordisk Inc |
| |||||
| Ranbaxy |
| |||||
| Santarus Inc |
| |||||
| Sb Pharmco |
| |||||
| Takeda Pharms Usa |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Metformin Hydrochloride, Riomet Er's active ingredient. Check the complete list of approved generic manufacturers for Riomet Er
About Riomet Er
Riomet Er is a drug owned by Sun Pharmaceutical Industries Ltd. Riomet Er uses Metformin Hydrochloride as an active ingredient. Riomet Er was launched by Sun Pharm in 2019.
Approval Date:
Riomet Er was approved by FDA for market use on 29 August, 2019.
Active Ingredient:
Riomet Er uses Metformin Hydrochloride as the active ingredient. Check out other Drugs and Companies using Metformin Hydrochloride ingredient
Dosage:
Riomet Er is available in for suspension, extended release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 500MG/5ML | FOR SUSPENSION, EXTENDED RELEASE | Discontinued | ORAL |